Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

April 22, 2024

https://www.globenewswire.com/news-release/2024/04/22/2866770/0/en/Cognition-Therapeutics-KOL-Event-Provided-Platform-for-Valuable-Discussion-of-Current-Therapeutic-Options-and-Need-for-Additional-Options-to-Treat-Alzheimer-s-Disease.html

PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, provided a recap of the virtual KOL event hosted on April 12, 2024 featuring Martin J. Sadowski, MD, PhD, DSci of the NYU School of Medicine; Anton Porsteinsson, MD of the University of Rochester Alzheimer’s Disease Care, Research and Education Program; and Everard (Jort) Vijverberg, MD, PhD of the Alzheimer Center Amsterdam and Neuroscience Amsterdam.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.